Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Virus or component thereof
Reexamination Certificate
2007-05-22
2007-05-22
Salimi, Ali R. (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Virus or component thereof
C435S069100, C435S069300, C530S300000
Reexamination Certificate
active
10371846
ABSTRACT:
Recombinant papillomavirus capsid proteins that are capable of self assembly into capsomer structures and viral capsids that comprise conformational antigenic epitopes are provided. The capsomer structures and viral capsids, consisting of the capsid proteins that are expression products of a bovine, monkey or human papillomavirus L1 conformational coding sequence proteins, can be prepared as vaccines to induce a high titer neutralizing antibody response in vertebrate animals. The self assembling capsid proteins can also be used as elements of diagnostic immunoassay procedures for papillomavirus infection.
REFERENCES:
patent: 4368149 (1983-01-01), Masuho et al.
patent: 4520113 (1985-05-01), Gallo et al.
patent: 4551270 (1985-11-01), Danos et al.
patent: 4671958 (1987-06-01), Rodwell et al.
patent: 4748109 (1988-05-01), Baird
patent: 4777239 (1988-10-01), Schoolnik et al.
patent: 4816397 (1989-03-01), Boss et al.
patent: 4983728 (1991-01-01), Herzog et al.
patent: 5039607 (1991-08-01), Skold et al.
patent: 5045447 (1991-09-01), Minson
patent: 5057411 (1991-10-01), Lancaster et al.
patent: 5071757 (1991-12-01), Kreider et al.
patent: 5081029 (1992-01-01), Zarling et al.
patent: 5180806 (1993-01-01), Dillner et al.
patent: 5186933 (1993-02-01), Estes
patent: 5437951 (1995-08-01), Lowy et al.
patent: 5618536 (1997-04-01), Lowy et al.
patent: 5709996 (1998-01-01), Lowy et al.
patent: 5716620 (1998-02-01), Lowy et al.
patent: 5744142 (1998-04-01), Lowy et al.
patent: 5756284 (1998-05-01), Lowy et al.
patent: 5855891 (1999-01-01), Lowy et al.
patent: 5871998 (1999-02-01), Lowy et al.
patent: 5874089 (1999-02-01), Schlegel et al.
patent: 5888516 (1999-03-01), Jansen et al.
patent: 5985610 (1999-11-01), Lowy et al.
patent: 6331415 (2001-12-01), Cabilly et al.
patent: 6485728 (2002-11-01), Schlegel et al.
patent: 0133123 (1984-07-01), None
patent: 0 133 123 (1985-02-01), None
patent: 0 256 321 (1988-02-01), None
patent: 0 343 783 (1989-11-01), None
patent: 0 390 252 (1990-10-01), None
patent: 0 451 550 (1991-10-01), None
patent: WO 90/10459 (1990-09-01), None
patent: WO 90/10867 (1990-09-01), None
patent: WO 9010459 (1990-09-01), None
patent: WO 91/04330 (1991-04-01), None
patent: WO 91/18118 (1991-11-01), None
patent: WO 91/18294 (1991-11-01), None
patent: WO 9118118 (1991-11-01), None
patent: WO 93/02184 (1993-01-01), None
patent: WO 93/02184 (1993-02-01), None
patent: WO 9302184 (1993-02-01), None
patent: WO 94/00152 (1994-01-01), None
patent: WO 9400152 (1994-01-01), None
patent: WO 94/20137 (1994-09-01), None
patent: WO 9420137 (1994-09-01), None
patent: WO 99/01557 (1999-01-01), None
patent: WO 00/23955 (2000-04-01), None
patent: WO 03/001208 (2003-01-01), None
Andrews and Pereira. 1978. “Reovirus” inViruses of Vertebrates, third edition. Bailliere Tyndall London p. 57-60.
Bachmann et al. (1997) Neutralizing Antiviral B Cell Responses, Annual Rev. Immunol., 15:235-270.
Baker (1987) Sequence Analysis of Papillomavirus Genomes, inThe Papovaviridae, Plenum Press, New York, pp. 321-385.
Baker et al. (1991) Structures of Bovine and Human Papillomaviruses, Analysis by cryoelectron microscopy and three-dimensional image reconstruction, Biophys. J. 60:1445-1456.
Baisley et al. (2000) Progress in the Development of Human Papillomavirus Vaccine for HPV-11 and HPV-16/18 and Mapping of a Critical Neutralizing Epitope, 18thInternational Papillomavirus Conference 2000 (Abstract).
Beiss et al. (1991) Type-specific and cross-reactive epitopes in human papillomavirus type 16 capsid proteins, Virology 184:460-464.
Bernard et al. (1994) Evolution of Papillomaviruses. Curr. Top. Micro. and Immuno. 186:33-54.
Bertioli et al. (1991) Transgenic plants and insect cells expressing the coat protein of arabis mosaic virus produce empty virus-like particles, J. Gen. Virol. 72:1801-1809.
Bonnez et al. (1990) Neutralization of HPV-11 Infection by Specific Polyclonal Antiserum Directed Against HPV-11 Viral Particles, Abstract at the Papillomavirus Workshop, Heidelberg, Germany May 12-17, 1990.
Bonnez et al. (1990) Use of HPV-11 Viral Particles in an ELISA to Detect Antibodies (Ab) in Humans with or withoutCondylomata acuminata(CA), Abstract at the Papillomavirus Workshop, Heidelberg, Germany May 12-17, 1990.
Bonnez et al. (1990) The Pstl-Xholl Restriction Fragment of the HPV-6b L1 ORF Lacks Immunliogical Specificity as Determined by Sera From HpvBCondyloma acuminatumPatients and Controls. Papillomaviruses p. 77-80.
Bonnez et al. (1991) Use of Human Papillomavirus Type 11 Virions in an ELISA to Detect Specific Antibodies in Humans withCondylomata acuminata, J. Gen. Virol. 72:1343-47.
Bonnez et al. (1992) Antibody Response to Human Papillomavirus (HPV) Type 11 in Children with Juvenile-Onset Recurrent Respiratory Papillomatosis (RRP), Virology 188:384-387.
Bonnez et al. (1992) Antibody-Mediated Neutralization of Human Papillomavirus Type 11 (HPV-11) Infection in the Nude Mouse: Detection of HPV-11 mRNAs, J. Infectious Diseases 165:376-80.
Bradley et al. (1980) Antigen-induced T cell proliferative responses, In Vitro Immune Responses, pp. 164-166.
Breitburd et al. (1981) Detection and Characterization of Viral Genomes and Search for Tumoral Antigens in Two Hamster Cell Lines Derived from Tumors Induced by Bovine Papillomavirus Type 1, Int. J. Cancer 27:693-702.
Breitburd (1987) Cell Culture Systems for the Study of Papillomaviruses, in Papillomaviruses and Human Disease 371-92 (Syrjänen et al., eds.).
Breitburd et al. (1995) Immunization with Viruslike Particles from Cottontail Rabbit Papillomavirus (CRPV) Can Protect against Experimental CRPV Infection, J. of Virol., 69:3959-3963.
Breitburd et al. (1997) The Rabbit Viral Skin Papillomas and Carcinomas: A Model for the Immunogenetics of HPV-Associated Carcinogenesis, Clinics in Dermatology, 15:237-247.
Broker (1987) Structure and Genetic Expression of Papillomaviruses, Obstet. Gynecol. Clin. North Am. 14:329-348.
Brown et al. (1991) Assembly of Empty Capsids by Using Baculovirus Recmbinants Expressing Human Parvovirus B19 Structural Proteins. J. Virol. 65: 2702-2706.
Brown et al. (2001) Neutralization of Human Papillomavirus Type 11 (HPV-11) by Serum from Women Vaccinated with Yeast-Derived HPV-11 L1 Virus-like Particles: Correlation with Competitive Radioimmunoassay Titer. J. Infect. Dis. 184:1183-86.
Brown et al (2001) 19th International Papillomavirus Conference, Brazil, Abstract O-51.
Browne et al. (1988) Analysis of the L1 Gene Product of Human Papillomavirus Type 16 by Expression in a Vaccinia Virus Recombinant. J. Gen. Virol. 69: 1263-1273.
Burnette et al. (1990) Induction of Bovine Papillomavirus E2 Gene Expression and Early Region Transcription by Cell Growth Arrest: Correlation with Viral DNA Amplification and Evidence for Differential Promoter Induction, J. Virol. 64:5529-5541.
Campo (1991) Vaccination against Papillomavirus, Cancer Cells 3(11):421-426.
Campo et al. (1993) Prophylactic and Therapeutic Vaccination Against a Mucosal Papillomavirus, J. Gen. Virol. 74:945-53.
Campo (1997) Vaccination against Papillomavirus in Cattle, Clinics in Dermatology 15:275-283.
Carter et al. (1991) Expression of Human Papillomavirus Proteins in YeastSaccharomyces cerevisiae. Virology 182: 513-21.
Carter et al. (1993) HPV-1 Capsids Expressed in Vitro Detect Human Serum Antibodies Associated with Foot Warts. Virology 195: 456-62.
Carter et al. (1994) Use of HPV 1 Capsids Produced by Recombinant Vaccinia Viruses in an ELISA to Detect Serum Antibodies in People with Foot Warts. Virology 199: 284-291.
Carter et al. (1995) Use of Human Papillomavirus Type 8 Capsids to Detect Antibodies in People with Genital Warts. J. Infect. Dis. 172:11-18.
Carter et al. (1996) The Natural History of Human Papillomavirus Type 16 Capsid Antibodies among a Cohort of University Women, J. of Infect. Diseases, 174:927-936.
Carter et al. (1997) Humoral Immune Repsonse to Human Papillomavirus Infection. Clinics in Dermatology 15:249-259.
Cason, et al. (1989) Identification of Immunogenic Regions of the Major Coat Protein of Human Papillomavirus Type 16 that Contain Type-restri
Kirnbauer Reinhard
Lowy Douglas R.
Schiller John T.
Knobbe Martens Olson & Bear LLP
Salimi Ali R.
The United States of America, as represented by the Secretary, D
LandOfFree
Self-assembling recombinant papillomavirus capsid proteins does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Self-assembling recombinant papillomavirus capsid proteins, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Self-assembling recombinant papillomavirus capsid proteins will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3747473